New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control
Recruiting now
This study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC